Ibutilide – recent molecular insights and accumulating evidence for use in atrial flutter and fibrillation

Bibliography

• HO KK, PINSKY JL, KANNEL W13, LEVY D: The epidemiology of heart failure: the Framingham study. J. Am. Coll. CardioL (1993) 22:6A–13A.
   Google Scholar
• BENJAMIN EJ, WOLF PA, D'AGOSTINO RB et al.: Impact of atrial fibrillation on the risk of death. The Framingham heart study. Circulation (1998) 98:946–952.
   PubMed Web of Science ®Google Scholar
• NATTEL S: New ideas about atrialfibrillation 50 years on. Nature (2002) 415:219–226.
   PubMed Web of Science ®Google Scholar
• LLOYD-JONES DM, WANG TJ,LEIP EP et al.: Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation (2004) 110:1042–1046.
   PubMed Web of Science ®Google Scholar
• GO AS, HYLEK EM, PHILLIPS KA et aL: Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. /AMA (2001) 285:2370–2375.
   PubMed Web of Science ®Google Scholar
• WANG TJ, PARISE H, LEVY D et aL: Obesity and the risk of new-onset atrial fibrillation. JAMA (2003) 292:2471–2477.
   Web of Science ®Google Scholar
• MATHEW JP, PARKS P, SAVINO JS et aL: Atrial fibrillation following coronary artery bypass graft surgery. JAMA (1996) 276:300–306.
   PubMed Web of Science ®Google Scholar
• HART RG, HALPERIN JL: Atrial fibrillation and stroke: concepts and controversies. Stroke (2001)32: 803–808.
   PubMed Web of Science ®Google Scholar
• NACCARELLI GV, WOLBRETTE DL, BHATTA Let aL: A review of clinical trials assessing the efficacy and safety of newer antiarrhythmic drugs in atrial fibrillation. J. Interv. Card. Electrophysiol. (2003) 9:215–222.
   PubMed Web of Science ®Google Scholar
• ECHT DS, LIEBSON PR, MITCHELL LB AND CAST INVESTIGATORS: Mortality and morbidity in patients receiving encainide, flecainide or placebo: The Cardiac Arrhythmia Suppression Trial. N EngL Med. (1991) 324:781–788.
   PubMed Web of Science ®Google Scholar
• THE CARDIAC ARRHYTHMIA SUPPRESSION TRIAL II INVESTIGATORS: Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N EngL J. Med. (1992) 327:227–233.
   PubMed Web of Science ®Google Scholar
• WALDO AL, CAMM AJ, DERUYTER H et al.: Effects of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. (The SWORD investigators). Lancet (1996) 348:7–12.
   PubMed Web of Science ®Google Scholar
• VISKIN S: Long QT syndromes and torsade de pointes. Lancet (1999) 354:1625–1633.
   PubMed Web of Science ®Google Scholar
• WITCHEL HJ, HANCOX JC: Familial and acquired long QT syndrome and the cardiac rapid delayed rectifier potassium current. Clin. Exp. Pharmacol. PhysioL (2000) 27:753–766.
   PubMed Web of Science ®Google Scholar
• VANDENBERG JI, WALKER BD, CAMPBELL TJ: HERG IQ channels: friend and foe. Trends Pharmacol. (2001) 22:240–246.
   PubMed Web of Science ®Google Scholar
• HESTER JB, GIBSON JK, CIMINI MG:N-Romega-amino-1-hydroxyalkyl)phenyllmethanesulfonamide derivatives with class III antiarrhythmic activity./ Med. Chem. (1991) 34:308–315.
   PubMed Web of Science ®Google Scholar
• •Original description of the chemistry of ibutilide.
   Google Scholar
• YANG T, SNYDERS DJ, RODEN DM: Ibutilide, a methanesulfonanilide antiarrhythmic, is a potent blocker of the rapidly activating delayed rectifier IQ-current (1,) in AT-1 cells. Concentration-, time-, voltage-, and use-dependent effects. Circulation (1995) 91:1799–1806.
   Google Scholar
• •Idenitification of ibutilide as an II, inhibitor.
   Google Scholar
• PERRY M, DE GROOT MJ, HELLI WELL R et aL: Structural determinants of HERG channel block by clofilium and ibutilide. MoL Pharmacol. (2004) 66: 240–249.
   PubMed Web of Science ®Google Scholar
• ••Detailed investigation reporting themolecular determinants of HERG channel blockade by ibutilide.
   Google Scholar
• LEE KS: Ibutilide, a new compound with potent class III antiarrhythmic activity, activates a slow inward Na* current in guinea pig ventricular cells. J. Pharmacol, Exp. Ther. (1992) 262:99–108.
   PubMed Web of Science ®Google Scholar
• ••First study identifying persistent Na*current activation by ibutilide.
   Google Scholar
• LEE KS, LEE EW: Ionic mechanism of ibutilide in human atrium: evidence for a drug-induced Na* current through a nifedipine inhibited inward channel. Pharmacol. Exp. Ther. (1998) 286:9–22.
   PubMed Web of Science ®Google Scholar
• ••Further characterisation of the persistentNa* current involved in the action of ibutilide.
   Google Scholar
• LEE KS, TSAI TD, LEE EW: Membrane activity of class III antiarrhythmic compounds; a comparison between ibutilide, d-sotalol, E-4031, sematilide and dofetilide. Eur. j Pharmacol. (1993) 234:43–53.
   PubMed Web of Science ®Google Scholar
• MITCHESON JS, PERRY MD: Moleculardeterminants of high-affinity drug binding to HERG channels. Curr. Opin. Drug Discov. DeveL (2003) 6:667–674.
   PubMed Web of Science ®Google Scholar
• LYNCH JJ JR, BASKIN EP, NUTT EM et aL: Comparison of binding to rapidly activating delayed rectifier IQ- channel, IK„ and effects on myocardial refractoriness for class III antiarrhythmic agents. Cardiovasc. Pharmacol. (1995) 25:336–340.
   PubMed Web of Science ®Google Scholar
• SATO N, TANAKA H, HABUCHI Y, GILES WR: Electrophysiological effects of ibutilide on the delayed rectifier K(+) current in rabbit sinoatrial and atrioventricular node cells. Eur. Pharmacol. (2000) 404:281–288.
   PubMed Web of Science ®Google Scholar
• •Describes modulation of nodal cell electrophysiology by ibutilide.
   Google Scholar
• YANG T, SNYDERS D, RODEN DM: Drug block of I(kr): model systems and relevance to human arrhythmias. Cardiovasc. Pharmacol. (2001) 38:737–744.
   PubMed Web of Science ®Google Scholar
• TWEEDIE D, HENDERSON C, KANE K: Glibenclamide, but not class III drugs, prevents ischaemic shortening of the refractory period in guinea-pig hearts. Eur. Pharmacol. (1993) 240:251–257.
   PubMed Web of Science ®Google Scholar
• FRIEDRICHS GS, CHI L, BLACK SC et al.: Antifibrillatory effects of ibutilide in the rabbit isolated heart: mediation via ATP-dependent potassium channels. Pharmacol. Exp. Ther. (1993) 266:1348–1354.
   PubMed Web of Science ®Google Scholar
• MITCHESON JS, CHEN J, LIN M, CULBERSON C, SANGUINETTI MC: A structural basis for drug-induced long QT syndrome. Proc. Natl. Acad. Sci. USA (2000) 97:12329–12333.
   PubMed Web of Science ®Google Scholar
• REIFFEL JA, BLITZER M: The actions of ibutilide and class Ic drugs on the slow sodium channel: new insights regarding individual pharmacologic effects elucidated through combination therapies. Cardiovasc. PharmacoL Ther. (2000) 5:177–181.
   PubMedGoogle Scholar
• WOOD Mk FULLER I, HONG A: Effects of sodium channel blockade on ibutilide induced prolongation of repolarization in the isolated rabbit ventricle. J. Interv. Card. ElectrophysioL (2000) 4:481–487.
   PubMed Web of Science ®Google Scholar
• WOOD Mk GILLINGAN DM, BROWN-MAHONEY C et al.: Clinical and electrophysiologic effects of calcium channel blockers in patients receiving ibutilide. Am. Heart J. (2002) 143:176–180.
   Google Scholar
• •Discusses whether an interaction of ibutilide occurs with Ca2* channel blockers clinically.
   Google Scholar
• MURRAY KT: Ibutilide. Circulation (1998) 97:493–487.
   PubMedGoogle Scholar
• •Previous review of ibutilide.
   Google Scholar
• NACCARELLI GV, LEE KS, GIBSON JK, VANDERLUGT J: Electrophysiology and pharmacology of ibutilide. Am. J. CardioL (1996) 78:12–16.
   PubMedGoogle Scholar
• •Early review of ibutilide.
   Google Scholar
• ELLENBOGEN KA, CLEMO HF, STAMBLER BS, WOOD MA, VANDERLUGT JT: Efficacy of ibutilide for termination of atrial fibrillation and flutter. Am J. CardioL (1996) 78:42–45.
   PubMed Web of Science ®Google Scholar
• CIMINI MG, BRUNDEN MN, GIBSON JK: Effects of ibutilide fitmarate, a novel antiarrhythmic agent, and its enantiomers on isolated rabbit myocardium. Eur. j PharmacoL (1992) 222:93–98.
   PubMed Web of Science ®Google Scholar
• HSU CY, WALTERS RR: Pharmacokinetics of ibutilide and its enantiomers in dogs. Chirality (1996) 8:18–23.
   PubMed Web of Science ®Google Scholar
• HUMPHREY SJ, SMITH MP, HSU CY, WALTERS RR: Cardiovascular effects of the R- and S-enantiomers of ibutilide in conscious beagle dogs. Methods Find. Exp. Clin. PharmacoL (2001) 23:449–455.
   PubMed Web of Science ®Google Scholar
• KNOBLOCH K, BRENDEL J, PEUKERT S et al.: Electrophysiological and antiarrhythmic effects of the novel I (Kur) channel blockers, S9947 and S20951, on left versus right pig atrium in vivo in comparison with the I(Kr) blockers dofetilide, azimilide, d,l-sotalol and ibutilide. Naunyn Schmiebergs Arch. PharmacoL (2002) 366:482–487.
   Google Scholar
• OSHIKAWA N, WATANABE I, MASAKI R et al.: Frequency-dependent electrophysiological effects of ibutilide on human atrium and ventricle. J. Interv. Card. ElectrophysioL (2001) 5:81–87.
   PubMed Web of Science ®Google Scholar
• STAMBLER BS, BECKMAN KJ, KADISH AH et al.: Acute hemodynamic effects of intravenous ibutilide in patients with or without reduced left ventricular fraction. Am. J. CardioL (1997) 80:458–463.
   PubMed Web of Science ®Google Scholar
• BUCHANAN LV, KABELL G, TURCOTTE UM, BRUNDEN MN, GIBSON JK: Effects of ibutilide on spontaneous and induced ventricular arrhythmias in 24-hour canine myocardial infarction: a comparative study with sotalol and encainide. j Cardiovasc. PharmacoL (1992) 19:256–263.
   PubMed Web of Science ®Google Scholar
• BUCHANAN LV, TURCOTTE UM, KABELL GG, GIBSON JK: Antiarrhythmic and electrophysiologic effects of ibutilide in a chronic canine model of atrial flutter. J. Cardiovasc. PharmacoL (1993) 22:10–14.
   PubMed Web of Science ®Google Scholar
• •Early study of ibutilide in animal model of atrial flutter.
   Google Scholar
• NABIH MA, PRCEVSKI P, FROMM BS et at.: Effect of ibutilide, a new class III agent, on sustained atrial fibrillation in a canine model of acute ischemia and myocardial dysfunction by microembolization. Pacing Clin. ElectrophysioL (1993) 16:1975–1983.
   Google Scholar
• BUCHANAN LV, KABELL G, GIBSON JK: Acute intravenous conversion of canine atrial flutter: comparison of antiarrhythmic agents. J. Cardiovasc. PharmacoL (1995) 25:539–544.
   PubMed Web of Science ®Google Scholar
• BUCHANAN LV, LEMAY RJ, WALTERS RR et al.: Antiarrhythmic and electrophysiologic effect of intravenous ibutilide and sotalol in the canine sterile pericarditis model. J. Cardiovasc. ElectrophysioL (1996) 7:113–119.
   PubMed Web of Science ®Google Scholar
• KHOURY DS, ASSAR MD, SUN H: Pharmacological enhancement of atrial defibrillation efficacy: role of ibutilide. J. Interv. Card. ElectrophysioL (1997) 1:291–298.
   PubMedGoogle Scholar
• WESLEY RC, FARKHANI F, MORGAN D, ZIMMERMAN D: Ibutilide: enhanced defibrillation via plateau sodium current activation. Am. J. PhysioL (1993) 264:H1269–H1274.
   PubMed Web of Science ®Google Scholar
• VERECKEI A, GORSKI JC, UJHELYI M, MEHRA R, ZIPES DP: Intrapericardial ibutilide administration fails to terminate pacing-induced sustained atrial fibrillation in dogs. Cardiovasc. Drugs Ther. (2004) 18:269–277.
   PubMed Web of Science ®Google Scholar
• VERECKEI A. WARMAN E, MEHRA R, ZIPES DP: Comparison of the effects on drug concentrations, electrophysiologic parameters, and termination of atrial fibrillation in dogs when procainamide and ibutilide are delivered into the right atrium versus intravenously. J. Cardiovasc. ElectrophysioL (2001) 12:330–336.
   PubMed Web of Science ®Google Scholar
• LABHASET WAR V, STRICKBERGER SA, UNDERWOOD T, DAVIS J, LEVY RJ: Prevention of acute inducible atrial flutter in dogs by using an ibutilide-polymer-coated pacing electrode. J. Cardiovasc. PharmacoL (1998) 31:449–455.
   PubMed Web of Science ®Google Scholar
• CHEN YJ, HSIEH MH, CHIOU CW, CHEN SA: Electropharmacologic characteristics of ventricular proarrhythmia induced by ibutilide. J. Cardiovasc. PharmacoL (1999) 34:237–247.
   PubMed Web of Science ®Google Scholar
• HSIEH MH, CHEN YJ, LEE SH: Proarrhythmic effects of ibutilide in a canine model of pacing induced cardiomyopathy. Pacing Clin. ElectrophysioL (2000) 23:149–156.
   PubMed Web of Science ®Google Scholar
• CHUGH SS, JOHNSON SB, PACKER DL: Altered response to ibutilide in a heart failure model. Cardiovasc. Res. (2001) 49:94–102.
   PubMed Web of Science ®Google Scholar
• GUO GB, ELLENBOGEN KA, WOOD MA, STAMBLER BS: Conversion of atrial flutter by ibutilide is associated with increased atrial cycle length variability. J. Am. Coll. CardioL (1996) 27:1083–1089.
   PubMed Web of Science ®Google Scholar
• STAMBLER BS, WOOD, MA, ELLENBOGEN KA et al.: Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation (1996) 94:1613–1621.
   PubMed Web of Science ®Google Scholar
• •Major clinical trial demonstrating the efficacy of ibutilide in atrial flutter and fibrillation.
   Google Scholar
• ABI-MANSOUR P, CARBERRY PA, McCOWAN RJ et al.: Conversion efficacy and safety of repeated doses of ibutilide in patients with atrial flutter and atrial fibrillation. Am. Heart J. (1998) 136:632–642.
   PubMed Web of Science ®Google Scholar
• STAMBLER BS, WOOD MA, ELLENBOGEN KA: Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation Circulation (1997) 96:4298–4306.
   Google Scholar
• ANTONICELLI R, TESTARMATA P, RECANATINI A: Ibutilide in rapid conversion of atrial flutter in octogenarians. Drugs Aging (2002) 19:787–791.
   PubMed Web of Science ®Google Scholar
• GOWDA RM, KHAN IA, PUNUKOLLU G et al.: Use of ibutilide for cardioversion of recent-onset atrial fibrillation and flutter in elderly. Am. J. Ther. (2004) 11:95–97.
   PubMedGoogle Scholar
• ELLENBOGEN KA, STAMBLER BS, WOOD MA et al.: Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J. Am. Coll. CardioL (1996) 28:130–136.
   PubMed Web of Science ®Google Scholar
• ZAQQA M, AFSHAR H, RASEKH A et al.: Predictors of conversion to sinus rhythm using ibutilide for atrial fibrillation or flutter. Am. J. CardioL (2000) 185:112–114.
   Google Scholar
• DAS MK, CHERIPARAMBIL K, BEDI A et al.: Cardioversion of atrial fibrillation with ibutilide: when is it not effective? Clin. CardioL (2002) 25:411–415.
   Web of Science ®Google Scholar
• VANDRLUGT JT, MATTIONI T, DENKER S et al.: Efficacy and safety of ibutilide fumarate for the conversion of atrial arrhythmias after cardiac surgery. Circulation (1999) 100:369–375.
   PubMed Web of Science ®Google Scholar
• •Important trial showing the efficacy of ibutilide in atrial arrhythmias after cardiac surgery.
   Google Scholar
• GLATTER K, YANG Y, CHATTERJEE K et al.: Chemical cardioversion of atrial fibrillation of flutter with ibutilide in patients receiving amiodarone therapy. Circulation (2001) 103:253–257.
   PubMed Web of Science ®Google Scholar
• VARRIALE P, SEDIGHI A, MIRZAITEHRANE M: Ibutilide for termination of atrial fibrillation in the Wolff-Parkinson-White syndrome. Pacing Clin. ElectrophysioL (1999) 22:1267–1269.
   PubMed Web of Science ®Google Scholar
• SOBEL RM, DHRUVA NN: Terminationof acute wide QRS complex atrial fibrillation with ibutilide. Am. J. Emerg-. Med. (2000) 18:462–464.
   PubMed Web of Science ®Google Scholar
• SANTINI M, PIGNALBERI C, RICCI R, CALO L, SANTINI L: Effectiveness of ibutilide in cardioversion of persistent atrial fibrillation in patients with dual chamber stimulation. J. Intern. Card. ElectrophysioL (2003) 9:15–20.
   PubMed Web of Science ®Google Scholar
• GLATTER KA, DOROSTKAR PC, YANG Yet al.: Electrophysiological effects of ibutilide in patients with accessory pathways. Circulation (2001) 104:1933–1999.
   Google Scholar
• •Interesting electrophysiological study of ibutilide in humans.
   Google Scholar
• DOMANOVITS H, SCHILLINGER M, THOENNISEN J et aL: Termination of recent-onset atrial fibrillation/flutter in the emergency department: a sequential approach with intravenous ibutilide and external electrical cardioversion. Resuscitation (2000) 45:181–187.
   PubMed Web of Science ®Google Scholar
• VARRIALE P, SEDIGHI A: Acute management of atrial fibrillation and atrial flutter in the critical care unit: should it be ibutilide? Clin. CardioL (2000) 265:265–268.
   Google Scholar
• CHILADAKIS JA, KALOGEROPOULOS A, PATSOURAS N, MANOLIS AS: Ibutilide added to propafenone for the conversion of atrial fibrillation and flutter. J. Am. Coll. CardioL (2004) 44:859–863.
   PubMed Web of Science ®Google Scholar
• HONGO RH, THEMISTOCLAKIS S, RAVIELE A et aL: Use of ibutilide in cardioversion in patients with atrial fibrillation or atrial flutter treated with class IC agents. J. Am. Coll. CardioL (2004) 44:864–868.
   PubMed Web of Science ®Google Scholar
• HENNERSDORF MG, PERINGS SM, ZUHLKE C et al.: Conversion of recent-onset atrial fibrillation or flutter with ibutilide after amiodarone has failed. Intensive Care Med. (2002) 28:925–929.
   PubMed Web of Science ®Google Scholar
• STAMBLER BS, WOOD MA, ELLENBOGEN KA: Comparative efficacy of intravenous ibutilide versus procainamide for enhancing termination of atrial flutter by atrial overdrive pacing. Am. J. Cardiol. (1996) 77:960–966.
   PubMed Web of Science ®Google Scholar
• ORAL H, SOUZA JJ, MICHAUD GF et aL: Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pre-treatment. N Engl. J. Med. (1999) 340:1849–1854.
   PubMed Web of Science ®Google Scholar
• LI H, NATALE A, TOMASSONI G et aL: Usefitlness of ibutilide in facilitating successful external cardioversion of refractory atrial fibrillation. Am. J. CardioL (1999) 84:1096–1098.
   PubMed Web of Science ®Google Scholar
• STICHERLING G, OZAYDIN M, TADA H et aL: Comparison of verapamil and ibutilide for the suppression of immediate recurrences of atrial fibrillation after transthoracic cardioversion. Cardiovasc. PharmacoL Ther. (2002) 7:155–160.
   PubMedGoogle Scholar
• MAZZA A, FERA MS, BISCEGLIA I et aL: Efficacy and safety of ibutilide versus transoesophageal atrial pacing for the termination of Type 1 atrial flutter. Europace (2004) 6:301–306.
   PubMedGoogle Scholar
• EFREMIDIS M, SIDERIS A, BATRA R et aL: Facilitating internal cardioversion of chronic atrial fibrillation with ibutilide-predictors of atrial defibrillation-threshold decrease. Med. Sci. Monit. (2004) 10:CR258–263.
   Google Scholar
• CHENG J, GLATTER K, YANG Yet aL:Electrophysiological response of the right atrium to ibutilide during typical atrial flutter. Circulation (2002) 106:814–819.
   PubMed Web of Science ®Google Scholar
• MURDOK DK, SCHUMOCK GT, KALIEBE J, OLSON K, GUENETTE AJ: Clinical and cost comparison of ibutilide and direct-current cardioversion for atrial fibrillation and flutter. Am. J. CardioL (2000) 85:505–506.
   Google Scholar
• ZARKIN GA, BALA MV, CALINGAERT B, VANDERLUGT JT: The cost-effectiveness of ibutilide versus electrical cardioversion in the conversion of atrial fibrillation and flutter to normal rhythm. Am. J. Manag-. Care (1997) 3:1387–1394.
   PubMed Web of Science ®Google Scholar
• STAMBLER BS, WOOD MA, ELLENBOGEN KA: Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation: electrophysiological determinants of enhanced conversion effect. Circulation (1997) 96:4298–4306.
   PubMed Web of Science ®Google Scholar
• VOLGMAN AS, CARBERRY PA, STAMBLER B et aL: Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. J. Am. Coll. CardioL (1998) 31:1414–1419.
   PubMed Web of Science ®Google Scholar
• REISINGER J, GATTERER E, LANG Wet aL: Flecainide versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset. Eur. Heart J. (2004) 25:1318–1324.
   PubMed Web of Science ®Google Scholar
• SOUCIER R, SILVERMAN D, ABORDO M et aL: Propafenone versus ibutilide for post operative atrial fibrillation following cardiac surgery: neither strategy improves outcomes compared to rate control alone (the PIPAF study). Med. Sci. Monit. (2003) 9:PI19–P123.
   Google Scholar
• VOS MA, GOLITSYN SR, STRANGL K et al.: Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. Heart (1998) 79:568–575.
   PubMed Web of Science ®Google Scholar
• BERNARD EO, SCHMID ER, SCHMIDLIN D et aL: Ibutilide versus amiodarone in atrial fibrillation: a double-blinded, randomized study. Crit. Care Med. (2003) 13:1031–1034.
   Google Scholar
• ORAL H, OZAYDIN M, TADA H et aL:Comparison of amiodarone versus ibutilide for the prevention of immediate recurrences of atrial fibrillation during pulmonary vein isolation. Am. J. CardioL (2002)90:492–495.
   PubMed Web of Science ®Google Scholar
• MILLER MR, McNAMARA RL, SEGAL JB et aL: Efficacy of agents for pharmacological conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta-analysis of trials. Fam. Pract. (2000) 49:1033–1046.
   Web of Science ®Google Scholar
• KOWEY PR, VANDERLUGT JT, LUDERER JR: Safety and risk/benefit of ibutilide for acute conversion of atrial fibrillation/flutter. Am. J. CardioL (1996) 78:46–52.
   PubMedGoogle Scholar
• P1-JAM TV ROSEN MR: Sex, hormones, and repolarization. Cardiovasc. Res. (2002) 53:740–751.
   PubMed Web of Science ®Google Scholar
• ABI-GERGES N, PHILP K, POLLARD C et aL: Sex differences in ventricular repolarization: from cardiac electrophysiology to Torsades de Pointes. Fundam. Clin. PharmacoL (2004) 18:139–151.
   PubMed Web of Science ®Google Scholar
• GOWDA RM, KHAN IA, PUNUKOLLA G et al.: Female preponderance in ibutilide-induced torsade de pointes. Int. J. CardioL (2004) 95:219–222.
   PubMed Web of Science ®Google Scholar
• JOHANSSON M, CARLSON L: Female gender does not influence the magnitude of ibutilide-induced repolarization delay and incidence of torsades de pointes in an in vivo model of the acquired long QT syndrome. J. Cardiovasc. PharmacoL Ther. (2001) 6:247–254.
   PubMedGoogle Scholar
• RODRIGUEZ I, KILBORN MJ, LIU XK,PEZZULLO JC, WOOSLEY RL: Drug-induced QT prolongation in women during the menstrual cycle. JAMA (2001) 285:1322–1326.
   PubMed Web of Science ®Google Scholar
• •Interesting study of the relationship of gender with drug-induced QT prolongation.
   Google Scholar
• WOOD MA, STAMBLER BS, ELLENBOGEN KA et al.: Suppression of inducible ventricular tachycardia by ibutilide in patients with coronary artery disease. Am. Heart J. (1998) 135:1048–1054.
   PubMed Web of Science ®Google Scholar
• GAITA F, GIUSTETTO C, BIANCHI F et al.: Short QT Syndrome: Pharmacological Treatment. J. Am. Coll. CardioL (2004) 43: 1494–1499.
   PubMed Web of Science ®Google Scholar
• BRUGADA R, HONG K, DUMAINE R et al.: Sudden death associated with short QT syndrome linked to mutations in HERG. Circulation (2004) 109:30–35.
   PubMed Web of Science ®Google Scholar
• BELLOCQ C, VAN GINNEKEN ACG, BEZZINA C et aL: Mutation in the KCNQI Gene Leading to the Short QT Interval Syndrome. Circulation (2004) 109:2394–2397.
   PubMed Web of Science ®Google Scholar
• HARG P, MADSEN S, AMLIE JP: Severe ibutilide-induced arrhythmia in patients with heart failure. Tidsskr. Nor. Laeeoren. (2001) 121:2834–2835.
   PubMedGoogle Scholar
• KALIS JS, SPENCER AP, TSIKOURIS JP et al.: Impact of prophylactic i.v. magnesium on the efficacy of ibutilide for conversion of atrial fibrillation or flutter. Am. J. Health Syst. Pharm. (2003) 60:2308–2312.
   Google Scholar
• GOWDA RM, PUNUKOLLU G, KHAN IA et al.: Ibutilide for pharmacological cardioversion of atrial fibrillation and flutter: impact of race on efficacy and safety. Am. J. Ther. (2003) 10:259–263.
   PubMedGoogle Scholar
• BORIANI G, DIEMBERGER I, BIFFI M, MARTIGNANI C, BRANZI A: Pharmacological cardioversion of atrial fibrillation: current management and treatment options. Drugs (2004) 64:2741–2762.
   PubMed Web of Science ®Google Scholar
• HESTER JB, GIBSON JK, BUCHANAN LV et al.: Progress toward the development of a safe and effective agent for treating re-entrant cardiac arrhythmias: synthesis and evaluation of ibutilide analogues with enhanced metabolic stability and diminished proarrhythmic potential. J. Med. Chem. (2001) 44:1099–1115.
   PubMed Web of Science ®Google Scholar
• ••Describes the development of ibutilideanalogues including trecetilide.
   Google Scholar
• BUIST SC, HSU CY, WALTERS RR: Sensitive determination of a new antiarrhythmic agent, trecetilide in plasma by high performance liquid chromatography with fluorescence detection. J. Chromatogr. A. (1998) 828:259–265.
   PubMed Web of Science ®Google Scholar
• GUPTA AK, MAHESHWARI A, THAKUR RK, LOKHANDWALA YY: Newer antiarrhythmic drugs. Indian Heart J. (2001) 53:354–360.
   PubMedGoogle Scholar